The efficacy and safety of quinupristin/dalfopristin for the treatment of infections cause by vancomycin-resistant Enterococcus faecium

A progressive increase in the incidence of vancomycin resistance in strains of Enterococcus faecium (VREF) has severely constrained treatment options for patients with infection caused by this emerging pathogen. Quinupristin/dalfopristin (Synercid), the first injectable streptogramin antibiotic, is...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 1999-08, Vol.44 (2), p.251
Main Authors: Moellering, R C, Linden, P K, Reinhardt, J, Blumberg, E A, Bompart, f, Talbot, G H, Synercid Emergency-Use Study Group
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A progressive increase in the incidence of vancomycin resistance in strains of Enterococcus faecium (VREF) has severely constrained treatment options for patients with infection caused by this emerging pathogen. Quinupristin/dalfopristin (Synercid), the first injectable streptogramin antibiotic, is active in vitro against VREF, with an MIC
ISSN:0305-7453
1460-2091